Kalderos’ Post

Join us on Thursday October 19th for our "Beyond the Script: Medicaid Value" event on LinkedIn! Discover the latest insights and innovations in Medicaid healthcare. Don't miss out on this valuable opportunity to learn and connect with industry experts. #PrimeTherapeutics #BeyondTheScript

Join us on Thursday October 19th for our "Beyond the Script: Medicaid Value" event on LinkedIn! Discover the latest insights and innovations in Medicaid healthcare. Don't miss out on this valuable opportunity to learn and connect with industry experts. #PrimeTherapeutics #BeyondTheScript

📣 We encourage the Centers for Medicare & Medicaid Services to share data sources under consideration prior to listening sessions so patients are able to provide feedback on the patient-centricity and relevance of the sources. #ValueOurHealth #HealthEquity 🗒 Read our full list of recommendations for #patient-focused listening sessions in #Medicare #drugpricing negotiations. #HealthEquity #ValueOurHealth

Join us on Thursday October 19th for our "Beyond the Script: Medicaid Value" event on LinkedIn! Discover the latest insights and innovations in Medicaid healthcare. Don't miss out on this valuable opportunity to learn and connect with industry experts. #PrimeTherapeutics #BeyondTheScript

Join us on Thursday October 19th for our "Beyond the Script: Medicaid Value" event on LinkedIn! Discover the latest insights and innovations in Medicaid healthcare. Don't miss out on this valuable opportunity to learn and connect with industry experts. #PrimeTherapeutics #BeyondTheScript

The Centers for Medicare & Medicaid Services announced the details of an "outcomes-based agreement" pilot program for new sickle cell anemia treatments. It's an innovative approach to holding drug manufacturers accountable: If a drug does not meet a preset, measurable goal (such as lowering pain-related hospital episodes over time), the manufacturers will have to rebate some of the costs back to #CMS. CMS's handling of this type of program is new; generally, it's left up to the states involved in the pilot. They hope this switch will level drug performance standards across the country. #healthinsurance #Medicare

CALLING ALL RARE DISEASE ADVOCATES! The Centers for Medicare & Medicaid Services need to hear from you by *July 2nd, 2024* about how to make patient and healthcare provider input in the #drugprice #negotiation #program under the #inflationreductionact #IRA work better and be more impactful. #CMS released the next set of guidances for the #IRA drug price negotiation program last week. One of the positives: the agency continues to be committed to incorporating the patient perspective in the drug price negotiation program and is explicitly seeking feedback on format, process, and other opportunities to make the listening sessions work better, be more impactful, and be more inclusive and accessible to patients, caregivers, and providers. Hopefully this will allow #CMS to gain meaningful, robust, and fit-for-purpose input on issues such as unmet medical need and therapeutic alternative, that we know can have a substantive impact on the negotiated price. To learn more go to https://lnkd.in/eKWMc7bW

More changes coming, are you prepared? We can help. Do you have Employees or dependents nearing 65, we have in house experts that can meet one on one or a group setting. Medicare for individuals has a myriad of options and causes confusion that are team can solve. Upcoming changes to Medicare Part D in 2025 heighten the importance of creditable coverage determinations for employer sponsored prescription drug plans, initially thought to lack a simplified method by the Centers for Medicare and Medicaid Services (“CMS”) but later reinstated for 2025 with anticipated future adjustments. Learn more: https://ow.ly/KJcK50SejA9

States with Medicaid and PrEP drug assistance programs (DAP) saw a 99% boost in PrEP usage. Demonstrating that when policies support affordable PrEP, we see a dramatic increase in coverage. Tell your representatives that funding gaps are affecting local implementation of expanding PrEP access. When policies support affordable PrEP, we see a dramatic increase in coverage. Find your representative here: https://bit.ly/your_rep Read the full report: https://lnkd.in/eGP3Ymwf Together, we can – and will – secure equitable PrEP access for all!

Today, Pfizer signed an important agreement with the US federal government that will make it easier for eligible patients to access our oral #COVID19 treatment, helps enable the U.S. to have a robust stockpile of this treatment for future use, and helps provide additional clarity on the commercial market for our #COVID19-related products, reducing future uncertainty.   Under this agreement, by January 2024, our oral treatment will be offered through commercial channels, not just the emergency federal channels created and used by the US government during the pandemic. As a result, more pharmacies, clinics and other healthcare sites are expected to be able to stock this treatment, making it more accessible for eligible patients across the US.   In addition, on behalf of the federal government, Pfizer will set up a patient assistance program for the uninsured and underinsured through 2028. Patients insured through federal programs such as Medicare and Medicaid will continue to receive treatment free of charge in 2024.   To learn more, please watch this video:   https://lnkd.in/e2qnJE6F